Literature DB >> 10037483

Antidepressants noncompetitively inhibit nicotinic acetylcholine receptor function.

J D Fryer1, R J Lukas.   

Abstract

Nicotinic acetylcholine receptors (nAChRs) are diverse members of the neurotransmitter-gated ion channel superfamily and play critical roles in chemical signaling throughout the nervous system. The present study establishes for the first time the acute functional effects of sertraline (Zoloft), paroxetine (Paxil), nefazodone (Serzone), and venlafaxine (Effexor) on two human and one chick nAChR subtype. This study also confirms previous findings of nAChR functional block by fluoxetine (Prozac). Function of human muscle-type nAChR (alpha1/beta gammadelta) in TE671/RD cells, human autonomic nAChR (alpha3/beta4alpha5 +/- beta2) in SH-SY5Y neuroblastoma cells, or chick V274T mutant alpha7-nAChR heterologously expressed in native nAChR-null SH-EP1 epithelial cells was measured using 86Rb+ efflux assays. Functional blockade of human muscle-type and autonomic nAChRs is produced by each of the drugs in the low to intermediate micromolar range, and functional blockade of chick V274T-alpha7-nAChR is produced in the intermediate to high micromolar range. Functional blockade is insurmountable by increasing agonist concentrations at each nAChR subtype tested for each of these drugs, suggesting noncompetitive inhibition of nAChR function. These studies open the possibilities that nAChR subtypes in the brain could be targets for therapeutic antidepressants and could play roles in clinical depression.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10037483     DOI: 10.1046/j.1471-4159.1999.0721117.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  32 in total

Review 1.  Antidepressants as analgesics: an overview of central and peripheral mechanisms of action.

Authors:  J Sawynok; M J Esser; A R Reid
Journal:  J Psychiatry Neurosci       Date:  2001-01       Impact factor: 6.186

2.  Non-competitive inhibitory activities of morphinan and morphine derivatives at the alpha 3 beta 4 Neuronal nicotinic acetylcholine receptor determined using nonlinear chromatography and chemometric techniques.

Authors:  Krzysztof Jozwiak; Ruin Moaddel; Rika Yamaguchi; Alexandre Maciuk; Irving W Wainer
Journal:  Pharm Res       Date:  2006-08-09       Impact factor: 4.200

Review 3.  Modulation of ligand-gated ion channels by antidepressants and antipsychotics.

Authors:  Gerhard Rammes; Rainer Rupprecht
Journal:  Mol Neurobiol       Date:  2007-04       Impact factor: 5.590

Review 4.  Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system.

Authors:  Antoine Taly; Pierre-Jean Corringer; Denis Guedin; Pierre Lestage; Jean-Pierre Changeux
Journal:  Nat Rev Drug Discov       Date:  2009-09       Impact factor: 84.694

5.  Nicotinic partial agonists varenicline and sazetidine-A have differential effects on affective behavior.

Authors:  Jill R Turner; Laura M Castellano; Julie A Blendy
Journal:  J Pharmacol Exp Ther       Date:  2010-04-30       Impact factor: 4.030

6.  Sigma-1 receptor ligands inhibit catecholamine secretion from adrenal chromaffin cells due to block of nicotinic acetylcholine receptors.

Authors:  Rebecca L Brindley; Mary Beth Bauer; Nolan D Hartley; Kyle J Horning; Kevin P M Currie
Journal:  J Neurochem       Date:  2017-09-19       Impact factor: 5.372

7.  Promoter IV-BDNF deficiency disturbs cholinergic gene expression of CHRNA5, CHRM2, and CHRM5: effects of drug and environmental treatments.

Authors:  Kazuko Sakata; Abigail E Overacre
Journal:  J Neurochem       Date:  2017-08-16       Impact factor: 5.372

Review 8.  Subtypes of nicotinic acetylcholine receptors in nicotine reward, dependence, and withdrawal: evidence from genetically modified mice.

Authors:  Christie D Fowler; Michael A Arends; Paul J Kenny
Journal:  Behav Pharmacol       Date:  2008-09       Impact factor: 2.293

Review 9.  Potential therapeutic uses of mecamylamine and its stereoisomers.

Authors:  Justin R Nickell; Vladimir P Grinevich; Kiran B Siripurapu; Andrew M Smith; Linda P Dwoskin
Journal:  Pharmacol Biochem Behav       Date:  2013-04-18       Impact factor: 3.533

10.  Nicotine and nicotinic receptor antagonists potentiate the antidepressant-like effects of imipramine and citalopram.

Authors:  Piotr Popik; Ewa Kozela; Martyna Krawczyk
Journal:  Br J Pharmacol       Date:  2003-07       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.